AtriCure (Nasdaq:ATRC) shares took a slight hit today on second-quarter results that were mixed compared to the consensus forecast.
The Mason, Ohio-based cardiac ablation device company posted losses of $14.8 million, or 32¢ per share, on sales of $84.5 million for the three months ended June 30, 2022, for a slight bottom-line gain on sales growth of 18.4%.
AtriCure’s adjusted losses per share, also registering at 32¢, came in 2¢ behind Wall Street, while sales topped estimates by 6.3%.
“We delivered a remarkable second quarter as we continue changing the standard of care for millions of patients globally,” AtriCure President and CEO Michael Carrel said in a news release. “Our results demonstrate the building strength of our portfolio of solutions, while continued product innovation, clinical science and physician education drive expansive, long-term growth opportunities.”
AtriCure said it expects to log adjusted losses per share of between $1.07 and $1.12 for the full year. The company set its sales guidance for between approximately $323 million and $333 million.
Shares of ATRC were down 2.8% at $48.30 in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.4%.
